Dronedarone (Multaq) (Dronedarone (Dronedaron)) and Ibrutinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A inhibition can increase ibrutinib exposure.
Clinical significance and safety
With Dronedarone (Multaq) and Ibrutinib, the oncology team generally needs to apply ibrutinib-specific treatment adjustment and close toxicity monitoring. Moderate inhibitors must not be incorrectly described as strong inhibitors or automatically assigned the same absolute restrictions. The required plan depends on the current product information and the patient’s treatment; do not make a dose change yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.